PROJECT

Projects

Environmental & Social Review Summary

Project Number

48804

Company Name

ASPEN TREASURY IRELAND LIMITED

Date ESRS Disclosed

Sep 4, 2024

Country

South Africa

Region

Africa

Last Updated Date

Oct 1, 2024

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jul 2, 2024
Signed : Aug 6, 2024
Invested : Sep 25, 2024

Sector

other

Industry

other

Department

Regional Industry - MAS Africa

Project Description

The proposed investment is an up to EUR500 million financing package comprising (i) an unsecured, straight senior loan (“A” loan) of up to EUR150 million from IFC and; (ii) mobilization of parallel loans of up to EUR350 million to Aspen Treasury Ireland Limited (ATIL), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited (Aspen or the Company). The financing will support: (i) Aspen’s corporate financing program to assist the Company in expanding its capacity to deliver medicines, diabetes insulin and pediatric vaccines in Africa; the Company’s investment in ongoing product development and acquisition of product portfolios; (iii) the Company’s investments in emerging markets manufacturing capabilities; and (iv) to refinance existing debt and strengthen the Company’s balance sheet (the ‘Project’).

 

The Company plans to use its existing sterile production facilities in Gqeberha for insulin, anesthetic and vaccine production, which will not require new land acquisition and is located in a light industrial zone. Similarly, most of the company operations are located in well-developed industrial zones.

 

Aspen is Africa’s largest pharmaceuticals company, a manufacturer and distributor of lifesaving medicines and Active Pharmaceutical Ingredients (‘APIs’). The Company’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Prescription, Over-the-counter and Injectables. The Company’s manufacturing footprint includes seven API and 16 Finished Dose Form (“FDF”) production facilities situated across Africa, Asia, Europe and the United States (US). The Company supplies medicines to over 115 emerging and developed countries (including more than 20 in Africa) through its 65 established offices in more than 50 countries.

 

In 2021, IFC provided a financing package to Aspen Finance Proprietary Limited, a wholly owned subsidiary of Aspen, to refinance existing debt and strengthen the Company’s balance sheet, supporting Aspen’s operations including the production of vaccines, and other therapies in African and emerging markets https://disclosures.ifc.org/project-detail/ESRS/45174/aspen-pharmacare .

Overview of IFC's Scope of Review

IFC reviewed Aspen’s Environmental and Social (‘E&S’) information, including: the Company’s corporate occupational safety, health and environmental (‘SHE’) policies, procedures and standards; human resources (‘HR’) policies, procedures and disclosures; SHE key performance indicators and 2022-2023 sustainability reports. Additionally, site appraisal visits were undertaken at Aspen’s API facilities in Cape Town, on November 6, 2023, FDF facilities in Dar es Salaam on November 14, 2023, and FDF facilities in Gqeberha (formally Port Elizabeth) on January 12, 2024. Finally, the appraisal included discussions with the Company’s senior management, corporate and facility level personnel responsible for SHE, HR management and utilities management via video conferencing and during the site visits.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement